ORLANDO, FL / ACCESS Newswire / March 14, 2025 / RedChip Companies will air interviews with Nexalin Technology, Inc. (Nasdaq:NXL) and Calidi ...
In a report released today, Wei Sim from Jefferies maintained a Buy rating on Nuix Ltd. (NXL – Research Report), with a price target of A$4.90.
David Owens, Chief Medical (TASE:PMCN) Officer and Director at Nexalin Technology , Inc. (NASDAQ:NXL), recently acquired 1,000 shares of the company's common stock. The purchase, executed on ...
Stay updated on market trends for NXL. EXCLUSIVE: Nexalin Technology Says New Data Confirms Investigational Non-Invasive Neurostimulation Device Improves Cognitive Function, Restores Brain ...
Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today ...
Upcoming dividends for Nuix Limited (NXL) are announced to the ASX several weeks before the ex-dividend date. To be a paid a dividend, you must own shares in Nuix Limited (NXL) before the ex-dividend ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Patent Strengthens Nexalin’s Intellectual Property Portfolio and Highlights the Potential of DIFS™ Technology in Addressing Substance Use Disorders, Including Opioids, Alcohol, Cocaine and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results